今年以来海思科已公布的国际专利申请5个，与去年同期持平。结合公司2025年中报财务数据，2025上 半年公司在研发方面投入了3.42亿元，同比增59.22%。 数据来源：企查查 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，根据企查查数据显示海思科（002653）公布了一项国际专利申请，专利名为"一种三环 稠杂环类PDE3/4双重抑制剂及其中间体的制备方法"，专利申请号为PCT/CN2025/114413，国际公布日 为2026年2月19日。 专利详情如下： 图片来源：世界知识产权组织（WIPO） ...

Group 1 - In 2025, China's foreign trade showed strong resilience, with total exports reaching a historical high, growing by 5.5% year-on-year, despite a complex external environment [1][57] - China's trade surplus exceeded $1 trillion for the first time, marking a significant increase of 19.8% year-on-year [1][57] - The net export of goods and services contributed 1.64 percentage points to GDP growth, the second-highest level since 2007, only behind 2021 [3] Group 2 - The diversification of external demand has strengthened, with emerging markets compensating for the decline in exports to the US, which fell by 19.79% year-on-year [6] - Exports to ASEAN, Africa, and the Middle East saw significant growth rates of 25.9%, 13.64%, and 9.7% respectively, contributing positively to the overall export scale [6] - The share of US exports in China's total exports decreased by 3.53 percentage points to 11.15% [6] Group 3 - The product structure of China's foreign trade is shifting towards higher value chains, with high-end products like electrical machinery, machinery, automobiles, and ships being the main export drivers [8] - Traditional light industrial products such as furniture and toys have seen a decline in export scale due to tariff friction and industrial chain relocation [8] Group 4 - The restructuring of global supply chains is creating significant opportunities for Chinese companies, with a notable increase in the number of Chinese enterprises establishing production capacities abroad, reaching 229 in 2025, nearly doubling from 2024 [18] - ASEAN, Mexico, and India are the primary destinations for Chinese production capacity outflows, with ASEAN covering a wide range of industries [18] Group 5 - The AI expansion cycle is a core focus in the Chinese capital market, with significant growth expected in AI computing hardware, supported by macro investment scales and healthy balance sheets of major tech companies [29][30] - The capital expenditure of major cloud service providers is projected to increase significantly, reflecting strong demand for AI computing [35] Group 6 - Cultural and technological value output is becoming a major trend for Chinese enterprises going abroad, with significant growth in IP exports and innovative products in sectors like gaming and new dining [39][41] - The Chinese innovative pharmaceutical sector is increasingly integrated into the global supply chain, with more products commercialized in the US and Europe [41] Group 7 - Key sectors with strong overseas expansion opportunities in 2026 include new energy (batteries, grid equipment), machinery, TMT (technology, media, telecommunications), and innovative pharmaceuticals [46] - The gaming industry is also highlighted for its potential, with significant overseas revenue growth expected [49]

Group 1 - The core issue involves investor claims against Nuotai Bio (688076) due to false statements leading to ongoing legal proceedings [1][5] - The Shanghai Financial Court has accepted the case for investor claims against Nuotai Bio, with further claims being processed [1][5] - Nuotai Bio's 2021 annual report was found to contain false records, including a reported revenue of 30 million yuan from a technology transfer that lacked commercial substance, inflating total revenue by 30 million yuan and profit by 25.95 million yuan, which accounted for 20.64% of the reported profit [1][5] Group 2 - Investors who purchased Nuotai Bio shares between April 28, 2022, and October 24, 2024, and sold or held shares after October 24, 2024, are eligible to file claims [2][6] - The law firm is also handling claims for Century Huatong (002602), with a recent filing submitted to the Shaoxing Intermediate People's Court [2][6] - Century Huatong was found to have false records in its annual reports from 2018 to 2022, including fabricated software copyright transfer transactions and premature revenue recognition [3][7] Group 3 - Investors who bought Century Huatong shares between April 27, 2019, and July 25, 2023, and sold or held shares after July 25, 2023, can initiate claims [4][8] - The law firm has a history of successfully representing investors in similar cases, with many having received compensation [4][8]

Core Viewpoint - Zai Lab (688266) has entered a strategic collaboration with AbbVie for the global development and commercialization of ZG006, receiving an upfront payment of $100 million and potential milestone payments up to $1.075 billion, along with tiered royalties [1][4]. Group 1: Company Developments - Zai Lab's stock price increased by 3.27% this week, closing at 94.42 CNY, with a market capitalization of 24.994 billion CNY, ranking 16th in the chemical pharmaceutical sector [1]. - ZG006 has shown significant efficacy in treating small cell lung cancer, with an overall response rate (ORR) of 60.0% in the recommended dose group and a confirmed ORR of 53.3% [1][4]. - ZG005 has demonstrated an ORR of 40.9% in second-line and above cervical cancer patients, with a median progression-free survival (mPFS) exceeding 11 months [2][4]. - The injection of human thyroid-stimulating hormone beta (Zesuneng) was approved on January 8 for use in post-operative follow-up of differentiated thyroid cancer, with marketing efforts led by Merck in China [2][4]. - The drug Jikaxitini tablets were included in the national medical insurance directory effective January 1, 2026, and are recommended as a first-line treatment for anemia in myelofibrosis [2][4]. Group 2: Financial Performance - The company expects its revenue for 2025 to be between 796.49 million CNY and 828.99 million CNY, representing a year-on-year growth of 49.45% to 55.55%, primarily driven by increased sales of recombinant thrombin and the launch of Jikaxitini tablets [3][4]. - Despite revenue growth, the company anticipates a net loss due to increased sales and research expenses [3]. Group 3: Shareholder Actions - The chairman and major shareholder, Zelin Sheng, plans to reduce his holdings by up to 273,907 shares (0.1035%), while Ningbo Zeao intends to reduce its holdings by up to 2,475,090 shares (0.9350%) between March 17 and June 16, 2026 [3][4].

Core Viewpoint - The article discusses the current funding logic in the market, highlighting the significant movements of public funds in the technology sector, particularly in the semiconductor and biopharmaceutical industries, as they adjust their portfolios based on performance and valuation metrics [3][8]. Group 1: Public Fund Movements - Public funds have shown a notable shift in their holdings, particularly in the STAR Market, with the STAR 50 Index rising by 12.1% this year [3][4]. - The total market capitalization of STAR Market companies reached 10.4 trillion yuan, with the technology sector dominating, accounting for 62.1% of the total market cap [5][6]. - The semiconductor industry remains the core focus for fund allocation, with 12 companies in the sector having a market capitalization exceeding 10 billion yuan [9][11]. Group 2: Semiconductor Sector Insights - The market's pricing anchor for the semiconductor sector has shifted from "valuation expansion" to "performance realization," emphasizing the importance of actual earnings [13][14]. - Key drivers for future growth in the semiconductor sector include strong order backlogs, profit growth through acquisitions and expansions, and sustained price increases in advanced processes [13][14]. - Public funds have significantly increased their holdings in semiconductor materials, chip design, and equipment, with companies like ShenGong Co. seeing an 11% increase in fund holdings [15][21]. Group 3: Biopharmaceutical Sector Insights - The biopharmaceutical sector is a critical area for public funds, with major holdings in companies like BeiGene and United Imaging Healthcare, although the sector has faced a reduction in holdings for several key companies [24][26]. - The article notes that innovative drug companies are currently under pressure, with significant reductions in holdings observed in companies like BaiLi TianHeng and RongChang Biopharma [26][28]. - Despite the challenges, companies with strong earnings potential and innovative drug pipelines are still attracting interest from public funds, indicating a selective investment approach [35][40].

Recent Events - The control change plan has been terminated as of January 7, 2026, due to the failure of the controlling shareholder and the counterparty to reach an agreement, leading to stock resumption and subsequent price fluctuations. This matter is not expected to have a significant adverse impact on the company's operations, which remain normal [1]. Performance Overview - For the period from January to September 2025, the company achieved a revenue of 299 million yuan, representing a year-on-year growth of 2.74%. The net profit attributable to shareholders was 32.67 million yuan, reflecting a year-on-year increase of 36.41%. The company emphasized its core business in small molecule generic drugs, with project applications and approvals ranking among the industry leaders [2]. Stock Performance - As of February 13, 2026, the stock price of the company was 9.32 yuan per share, with a total market capitalization of 3.584 billion yuan. The stock has seen a cumulative decline of 23.86% this year, although it has increased by 1.53% in the last five trading days. On that day, there was a net inflow of 6.07 million yuan in principal funds, with a turnover rate of 0.98%. The company has appeared on the stock leaderboard four times this year, with the most recent occurrence on January 13 [3]. Company Status - In April 2025, the indirect controlling shareholder, Hualing Industrial Trade, was changed to a state-owned enterprise in Xinjiang, with Xinjiang Commercial and Material Asset Management Co., Ltd. holding 51% of the shares, ultimately supervised by the Xinjiang State-owned Assets Supervision and Administration Commission. This change may affect the company's long-term strategy. Currently, there are no other significant announcements from the company, but investors are advised to pay attention to regular financial reports and any official disclosures regarding control dynamics [4].

Group 1 - The stock price of Hanchang Group (600774) has shown relatively stable fluctuations over the past week, with a range of -0.10% and an amplitude of 4.68%. The closing price on February 13, 2026, was 9.82 yuan, with a single-day increase of 0.51% and a trading volume of 51.65 million yuan, indicating low short-term capital participation as the main capital outflow was 4.38 million yuan [1] - On February 9, 2026, a national drug procurement bidding was held, involving 316 types of chemical drugs, which may impact pricing and sales expectations in the pharmaceutical sector. Hanchang Group's main business includes chemical drug formulations, accounting for 47.74% of its operations [2] - According to the Q3 2025 financial report, Hanchang Group achieved an operating income of 764 million yuan from January to September 2025, a year-on-year decrease of 15.49%. However, the net profit attributable to shareholders increased significantly by 274.07% to 9.33 million yuan, mainly due to cost control and improvements in non-recurring income, although the overall profitability remains under pressure with a negative price-to-earnings ratio [3] Group 2 - Institutional attention towards Hanchang Group is low, with the latest sentiment being neutral and no recent research records. All institutional ratings are neutral, with no clear target price or profit forecast adjustments, indicating a lack of short-term expectations from the market [4]

Core Viewpoint - Tonghua Golden Horse has made significant progress in the development of its new chemical drug, Amber Dihydroaminoacridine Tablets, which has completed comprehensive review work and is now in the final review stage, marking it as a noteworthy event in the near term [2] Financial Performance - For the third quarter of 2025, the company reported revenue of 892 million yuan and a net profit attributable to shareholders of 24.96 million yuan [2]

Core Insights - Hong Kong's IPO fundraising reached a record high of $37.4 billion in 2025, surpassing the total of the previous three years combined, marking a return to the top of the global IPO market after four years [1][3] - The surge in IPOs is attributed to explosive growth in listed companies, with 612 applications received and 119 successful listings, a 68% increase year-on-year [3][5] - Key sectors driving this growth include pharmaceuticals and technology, with significant participation from companies already listed on A-shares [3][5] IPO Performance - The top 10 IPOs in Hong Kong raised a total of approximately 142.5 billion HKD, accounting for about 50% of the total fundraising for the year [6][7] - Notable IPOs include CATL, which raised over 41 billion HKD, and Zijin Mining, which raised approximately 28.7 billion HKD [6][7] - The average first-day gain for new listings was significant, with the highest being 363.75% for Nobikang [10][12] Market Trends - The proportion of IPOs with a market capitalization exceeding 10 billion HKD reached 56%, significantly higher than the 30% average over the past five years [5] - The IPO market showed signs of confidence, with a record low first-day failure rate of 28.83% [5] - A total of 19 companies achieved dual listings (A+H), the highest in recent years, primarily in information technology and new consumption sectors [16][18] Industry Highlights - The emergence of "first stocks" in various sectors, such as high-end tea and AI, reflects the market's recognition of leading companies in niche areas [19][20] - The IPO market remains active into 2026, with 21 companies already listed by February, raising a total of 791.17 million HKD, indicating a 1220% increase [29][30] - Predictions for 2026 suggest the potential for 150 to 200 new listings, with fundraising expected to exceed 300 billion HKD, reinforcing Hong Kong's position as a leading global IPO market [29][30]

Industry Overview - In 2025, the Chinese chemical industry is experiencing a complex situation of cyclical bottoming and structural optimization, with significant internal differentiation [2] - Traditional basic chemicals are seeing slowed growth and prominent supply-demand structural contradictions, while specific sub-sectors are maintaining strong growth, becoming new engines for industry development [2] High-Profit Sectors Analysis - The pharmaceutical sector, particularly in chemical preparations, has an average profit margin exceeding 22%, driven by rigid demand, aging population, and high entry barriers [6][7] - The raw materials segment also maintains a profit margin around 22%, with companies like Hai Sheng Pharmaceutical and Senxuan Pharmaceutical expected to exceed 30% in annual profit margins [6][7] - The rubber deep processing sector, benefiting from the rapid development of the new energy vehicle industry, has an average profit margin of about 22%, with companies like Litong Technology and Kelong New Materials showing average profitability above 24% [8][9] - The oil and gas sector, with an average profit margin of 22%, is experiencing profit improvements due to the gradual relaxation of oil exploration and extraction permissions by the government [10] Low-Profit Sectors Analysis - The gas sector, with an average profit margin below 3%, faces challenges from price volatility and regulatory constraints, limiting its growth potential [11] - The traditional chemical products sector also struggles with an average profit margin below 3%, impacted by overcapacity and weak demand [12][13] - The petrochemical trade sector, similarly, has an average profit margin below 3%, reflecting deep-seated contradictions of overcapacity and declining demand for refined oil products [13] - The chemical fiber sector is facing profitability issues due to low demand in textiles and oversupply of conventional fibers [13] Industry Insights - The chemical industry is highly influenced by macroeconomic factors, with demand being the core variable determining product prosperity [14] - Key trends for 2025 include a shift towards high-value-added segments, the rise of the new energy industry reshaping demand structures, and the release of policy dividends in oil and gas sectors [14] - Companies like Bluestar Technology demonstrate that differentiation and technological upgrades can provide pathways for success in overcapacity industries [14]